FORM OF CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN IMARA INC. and Dated as of [•]Contingent Value Rights Agreement • October 13th, 2022 • IMARA Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 13th, 2022 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [•], is entered into by and among Imara Inc. a Delaware corporation (“Public Company”), and [•], as initial Rights Agent (as defined herein).
FORM OF IMARA INC. SUPPORT AGREEMENTSupport Agreement • October 13th, 2022 • IMARA Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 13th, 2022 Company Industry JurisdictionThis Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Enliven Therapeutics, Inc. a Delaware corporation (“Merger Partner”), Imara Inc., a Delaware corporation (“Public Company”), and the undersigned stockholder (the “Stockholder”) of Public Company.
FORM OF LOCK-UP AGREEMENTLock-Up Agreement • October 13th, 2022 • IMARA Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 13th, 2022 Company Industry JurisdictionThe undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Imara Inc., a Delaware corporation (“Public Company”), has entered into an Agreement and Plan of Merger, dated as of October 13, 2022 (as the same may be amended from time to time, the “Merger Agreement”) with Iguana Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Public Company, and Enliven Therapeutics, Inc., a Delaware corporation (“Merger Partner”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.
AGREEMENT AND PLAN OF MERGER by and among IMARA INC., IGUANA MERGER SUB, INC. and ENLIVEN THERAPEUTICS, INC. Dated as of October 13, 2022Merger Agreement • October 13th, 2022 • IMARA Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 13th, 2022 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of October 13, 2022, is entered into by and among Imara Inc., a Delaware corporation (“Public Company”); Iguana Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Public Company (the “Merger Sub”); and Enliven Therapeutics, Inc. a Delaware corporation (“Merger Partner”).